2017 American Society of Clinical Oncology Annual Meeting *

June 2-6, 2017; Chicago, Illinois
This program provides coverage of the 2017 ASCO annual meeting with PowerPoint summaries and expert analysis of the key study results with downloadable slidesets. Tumor types covered include skin, hematologic, lung, gastrointestinal, genitourinary, gynecologic, and breast.

Share

Program Content

Activities

Top Studies Chicago 2017
Preview of ASCO 2017: Top Expert-Selected Studies
Clinical Thought
Conference Coverage
Congratulations: You achieved a completion on 04/09/2022

Released: May 31, 2017

Expires: May 30, 2018

Activities

IDEA: Adjuvant Oxaliplatin in Colon Cancer
IDEA: Pooled Analysis of Adjuvant Oxaliplatin for 3 vs 6 Mos in Stage III Colon Cancer
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 05, 2017

Expires: June 04, 2018

REFLECT: Lenvatinib in uHCC
REFLECT: Phase III Noninferiority Study of the Multikinase Inhibitor Lenvatinib vs Sorafenib as First-line Therapy in Unresectable Hepatocellular Carcinoma
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 05, 2017

Expires: June 04, 2018

AG-120 in IDH1-Mutant CC
Safety and Clinical Activity of Mutant IDH1 Inhibitor AG-120 in Pretreated IDH1-Mutant Cholangiocarcinoma
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 06, 2017

Expires: June 05, 2018

HALO-202: PEGPH20 in Pancreatic
Phase II HALO-202: nab-Paclitaxel and Gemcitabine ± PEGPH20 in Untreated Metastatic Pancreatic Ductal Adenocarcinoma
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 06, 2017

Expires: June 05, 2018

SIRveNIB: SIRT vs Sorafenib in HCC
SIRveNIB: Randomized Phase III Trial of Selective Internal Radiation Therapy vs Sorafenib in Locally Advanced HCC
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 07, 2017

Expires: June 06, 2018

BILCAP
BILCAP: Phase III Trial of Adjuvant Capecitabine for Biliary Tract Cancer
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 07, 2017

Expires: June 06, 2018

ASPECCT: ctDNA Analysis
Circulating Tumor DNA Analysis From Pts With mCRC Who Were Treated With Panitumumab in ASPECCT
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 08, 2017

Expires: June 07, 2018

mCRC: Vemurafenib Combination
SWOG S1406: Vemurafenib in Combination With Irinotecan and Cetuximab in BRAF V600E Metastatic CRC
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 12, 2017

Expires: June 11, 2018

KEYNOTE-059: Pembro in G/GEJ Cancer
KEYNOTE-059 (Cohort 1): Pembrolizumab Monotherapy in Previously Treated Advanced Gastric or GEJ Adenocarcinoma
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 13, 2017

Expires: June 12, 2018

Prognostic Markers in CRC
Prognostic Factors for First-line Chemotherapy + Bevacizumab or Cetuximab in Metastatic Colorectal Cancer
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 14, 2017

Expires: June 13, 2018

Activities

KEYNOTE-052: Pembro in UC
KEYNOTE-052: Updated Findings on First-line Pembrolizumab in Cisplatin-Ineligible Advanced Urothelial Cancer
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 08, 2017

Expires: June 07, 2018

ECHO-202: Epacadostat in RCC
ECHO-202/KEYNOTE-037: Phase I/II Study of Epacadostat + Pembrolizumab in Pts With Advanced RCC
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 08, 2017

Expires: June 07, 2018

KEYNOTE-045: Pembro vs CT in mUC
KEYNOTE-045: Updated Survival Analysis of Phase III Trial of Pembrolizumab vs Paclitaxel, Docetaxel, or Vinflunine in Pts With Advanced Urothelial Carcinoma
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 09, 2017

Expires: June 08, 2018

PROTECT: Adjuvant Pazopanib
PROTECT: Adjuvant Pazopanib After Nephrectomy in Pts With Locally Advanced RCC
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 13, 2017

Expires: June 12, 2018

ECHO-202/KEYNOTE-037
Phase Ib/II ECHO-202/KEYNOTE-037: Epacadostat + Pembrolizumab in Pts With Advanced Urothelial Carcinoma
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 14, 2017

Expires: June 13, 2018

Activities

RT + CT vs RT for EC
Combination Adjuvant Chemotherapy + Radiation Therapy vs Radiation Alone for High Risk Endometrial Carcinoma: Final Report From PORTEC-3
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 04, 2017

Expires: June 03, 2018

Nivo in R/M GYN Cancers
CheckMate 358: Phase I/II Evaluation of Nivolumab Monotherapy in Virus-Associated, Recurrent/Metastatic Gynecologic Cancers
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 04, 2017

Expires: June 03, 2018

LION: LNE for Advanced Ovarian Cancer
LION (Phase III Trial): Lymphadenectomy for LN-Negative Advanced Ovarian Cancer Following Complete Resection
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 05, 2017

Expires: June 04, 2018

SOLO2: Olaparib in Ovarian Cancer
SOLO2: Safety, HRQoL With Maintenance Olaparib in Germline BRCA-Mutated Platinum-Sensitive Relapsed Serous Ovarian Cancer
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 13, 2017

Expires: June 12, 2018

Activities

Pembro in mTNBC
KEYNOTE-086 (Cohort A): Phase II Evaluation of Pembrolizumab Monotherapy in Heavily Pretreated Metastatic TNBC
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 04, 2017

Expires: June 03, 2018

Ipatasertib + Pac in TNBC
LOTUS: Investigation of Ipatasertib, a Novel Akt Inhibitor, in Combination With Paclitaxel as Frontline Therapy for Metastatic TNBC
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 04, 2017

Expires: June 03, 2018

APHINITY: Pertuzumab in HER2+ EBC
APHINITY: Adjuvant Pertuzumab + Trastuzumab and Chemotherapy in HER2+ EBC
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 05, 2017

Expires: June 04, 2018

Dual HER2 Blockade + AI in MBC
ALTERNATIVE: Dual HER2 Blockade + Aromatase Inhibitor in Postmenopausal Women With HER2+, HR+ MBC
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 06, 2017

Expires: June 05, 2018

Carboplatin, Veliparib in Early TNBC
Phase III Investigation of Neoadjuvant Carboplatin ± Veliparib in Combination With Chemotherapy in Early-Stage TNBC
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 07, 2017

Expires: June 06, 2018

MONARCH 2
MONARCH 2: Phase III Study of Abemaciclib + Fulvestrant in HR+/HER2- Advanced Breast Cancer After Progression on Endocrine Therapy
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 07, 2017

Expires: June 06, 2018

SOLE: Letrozole Frequency
Phase III SOLE: Continuous vs Intermittent Letrozole After Adjuvant Endocrine Therapy in Early HR+ Breast Cancer
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 08, 2017

Expires: June 07, 2018

Olaparib in HER2-, <i>gBRCA</i>m MBC
OlympiAD: PARP Inhibitor Olaparib Monotherapy in HER2-Negative, BRCA-Mutated MBC
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 08, 2017

Expires: June 07, 2018

I-SPY 2: Pembrolizumab in EBC
I-SPY 2: Addition of Pembrolizumab to Neoadjuvant Chemotherapy in HER2-Negative Early Breast Cancer
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 09, 2017

Expires: June 08, 2018

PlanB: TC vs EC-T in HER2- EBC
Phase III PlanB Final Analysis: Adjuvant TC vs EC→T in Pts With High-Risk HER2-Negative Early Breast Cancer
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 12, 2017

Expires: June 11, 2018

TRAIN-2: Neoadjuvant CT ± Anthracyclines in HER2+ EBC
TRAIN-2 (BOOG 2012-03): Phase III Trial of Neoadjuvant Chemotherapy ± Anthracyclines With Dual HER2 Blockade in HER2+ EBC
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Activities

KEYNOTE-021 Cohort G
Pembrolizumab + Carboplatin and Pemetrexed in Previously Untreated, Advanced Nonsquamous NSCLC: Updated Results From KEYNOTE-021 Cohort G
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 04, 2017

Expires: June 03, 2018

irAEs With Immunotx Retreatment
Retrospective Analysis of Immunotherapy Retreatment Following Immune-Related AEs in NSCLC Pts Treated With Anti–PD-(L)1 Therapy
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 05, 2017

Expires: June 04, 2018

nab-P/carbo in High-Risk NSCLC
nab-Paclitaxel + Carboplatin in Higher-Risk Pt Populations With Advanced NSCLC
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 05, 2017

Expires: June 04, 2018

ADJUVANT: Gefitinib in <i>EGFR</i>mut+ NSCLC
ADJUVANT: Phase III Trial Evaluating Gefitinib vs Vinorelbine/Cisplatin in Completely Resected Stage II-IIIA (N1-N2) NSCLC With EGFR Activating Mutations
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 07, 2017

Expires: June 06, 2018

Post-PD Atezolizumab in NSCLC
OAK: Impact of Continued Atezolizumab Beyond PD in Pts With Advanced NSCLC
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 07, 2017

Expires: June 06, 2018

CheckMate 032: Nivo/Ipi in SCLC
Phase I/II CheckMate 032: Nivolumab ± Ipilimumab in Advanced SCLC
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 07, 2017

Expires: June 06, 2018

KEYNOTE-024 Update
KEYNOTE-024: Extended Survival Outcomes With First-line Pembrolizumab in PD-L1+ NSCLC
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 08, 2017

Expires: June 07, 2018

ALEX: Alectinib in <i>ALK</i>+ NSCLC
ALEX: Alectinib vs Crizotinib as First-line Therapy in Pts With ALK+ NSCLC
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 08, 2017

Expires: June 07, 2018

ARCHER 1050
ARCHER 1050: First-line Dacomitinib vs Gefitinib in EGFR-Mutant Advanced NSCLC
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 09, 2017

Expires: June 08, 2018

Osimertinib CNS response
AURA-3: CNS Response to Osimertinib in EGFR T790M+ Advanced NSCLC
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 09, 2017

Expires: June 08, 2018

Recurrent MPM: Nivo ± Ipi
MAPS-2 (IFCT-1501): Nivolumab ± Ipilimumab in Recurrent Malignant Pleural Mesothelioma
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Activities

ECHO-202/KEYNOTE-037
Phase I/II ECHO-202/KEYNOTE-037: Safety of Epacadostat + Pembrolizumab in Solid Tumors
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 05, 2017

Expires: June 04, 2018

KEYNOTE-006
KEYNOTE-006: Long-term Outcomes After Pembrolizumab for Advanced Melanoma
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 05, 2017

Expires: June 04, 2018

CheckMate 204: Nivolumab + Ipilimumab
CheckMate 204: Nivolumab + Ipilimumab in Pts With Advanced Melanoma and Asymptomatic, Untreated Brain Metastases
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 07, 2017

Expires: June 06, 2018

ECHO-204: Epacadostat/Nivo
ECHO-204: Preliminary Results of Phase I/II Trial of Epacadostat + Nivolumab in Advanced Solid Tumors
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 09, 2017

Expires: June 08, 2018

Ipi ± T-VEC in Melanoma
Phase II Trial of Ipilimumab ± Talimogene Laherparepvec in Unresected Stage IIIB-IV Melanoma
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Activities

BRIGHT: 5-Yr Results
BRIGHT: 5-Yr Follow-up of First-line BR vs R-CHOP/R-CVP in Pts With iNHL or MCL
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 05, 2017

Expires: June 04, 2018

Daratumumab + KRd in NDMM
Addition of Daratumumab to Carfilzomib, Lenalidomide, and Dexamethasone in Newly Diagnosed MM
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 06, 2017

Expires: June 05, 2018

GENUINE: Ublituximab in R/R CLL
GENUINE: Investigation of Ublituximab, a Novel CD20 Inhibitor, in Combination With Ibrutinib in Pts With Previously Treated High-Risk CLL
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 06, 2017

Expires: June 05, 2018

Elotuzumab + RVD in ND MM
Quadruple Therapy With Elotuzumab + RVD in Newly Diagnosed MM: Phase IIa Study
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 07, 2017

Expires: June 06, 2018

MAGNIFY: R/R FL Subanalysis
MAGNIFY Subanalysis: Lenalidomide + Rituximab Induction Followed by Maintenance in Pts With Early Relapsed or Double-Refractory FL
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 07, 2017

Expires: June 06, 2018

NDMM Induction: KCd vs KRd
FORTE: Induction With Carfilzomib, Dexamethasone, and Cyclophosphamide or Lenalidomide in Newly Diagnosed MM
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 07, 2017

Expires: June 06, 2018

OPTIMAL>60: RT by PET Status in DLBCL
OPTIMAL>60: Radiotherapy by PET Status After R-CHOP or R-CHLIP in Elderly Pts With DLBCL
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 08, 2017

Expires: June 07, 2018

PomdeSAR: Isatuximab in R/R MM
PomdeSAR: Early Investigation of the Anti-CD38 Monoclonal Antibody Isatuximab in Combination With Pomalidomide/Dexamethasone in R/R MM
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 08, 2017

Expires: June 07, 2018

Simplify 1: Momelotinib in MF
Simplify 1: Momelotinib vs Ruxolitinib in JAK Inhibitor–Naive Myelofibrosis
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 09, 2017

Expires: June 08, 2018

SIMPLIFY-2: Momelotinib vs BAT in MF
SIMPLIFY-2: Momelotinib vs Best Available Therapy in Ruxolitinib-Experienced Pts With Myelofibrosis
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 09, 2017

Expires: June 08, 2018

19-28z CAR T-Cells in R/R B-ALL
Phase I Trial of CD19-Targeted 19-28z CAR T-Cell Therapy in Adult Pts With R/R B-Cell ALL
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 12, 2017

Expires: June 11, 2018

Enasidenib in IDH2-Mutant R/R AML
Clinical Activity and Safety of IDH2 Inhibitor Enasidenib (AG-221) in IDH2-Mutant Relapsed/Refractory AML
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 12, 2017

Expires: June 11, 2018

CHRYSALIS: Molecular Responses With Gilteritinib
CHRYSALIS Exploratory Analysis: Molecular Responses With FLT3/AXL Inhibitor Gilteritinib in Relapsed/Refractory FLT3-ITD AML
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 14, 2017

Expires: June 13, 2018

MM: Denosumab vs ZA
Phase III Trial: Bone and Renal Effects With Denosumab vs Zoledronic Acid in Newly Diagnosed MM
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 14, 2017

Expires: June 13, 2018

Faculty

cover img faculity

Sara Hurvitz, MD

Assistant Professor of Medicine
Director, Breast Oncology Program
Division of Hematology-Oncology
Department of Internal Medicine
David Geffen School of Medicine at UCLA
Los Angeles, California

Provided by

ProCE Banner

Supporters

Supported by educational grants by

AbbVie

Amgen, Inc.

AstraZeneca

Celgene

Genentech Roche Virology

Halozyme

Incyte

Merck Oncology

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.